The NR1 gene undergoes induction in neurogenesis mainly via promoter de-repression, and up-regulation during neuronal differentiation by undefined mechanism(s). Here, we show that in the distal region the NR1 promoter has an active NF-B site sharing the consensus with the immunoglobulin (Ig)/human immunodeficiency virus NF-B site. Mutation of this site significantly reduced NR1 promoter up-regulation during neuronal differentiation of P19 cells. Electrophoretic mobility shift assays revealed that P19 nuclei constitutively contained p50 and that neuronal differentiation not only increased nuclear p50 but also induced p65 nuclear translocation. Responding to this change was an up-regulation of NF-B-dependent promoter activity. The N-methyl-D-aspartate (NMDA) 1 subtype of glutamate receptors plays an important role in neuronal differentiation and plasticity. The essential component of the NMDA receptor complexes is encoded by the NR1 gene (1, 2). This gene is induced during neurogenesis and up-regulated in neurons undergoing differentiation (3, 4). In studies of NR1 gene upregulation, a negative mechanism has been proposed: repressor element 1 (RE1) silencing transcription factor (REST)/neuronrestriction silencer factor (NRSF) acts on the RE1 site in the NR1 promoter and suppresses transcription in neural progenitors. After neurogenesis, REST/NRSF is down-regulated, and the suppression of the NR1 gene is removed to let de-repression occur (4). In studies of neuronal differentiation of P19 cells, we observed that there was a time gap between the down-regulation of the REST/NRSF protein and the gradually robust upregulation of the NR1 mRNA/promoter activity during neuronal differentiation (4), suggesting that a positive mechanism is required for NR1 gene transcription after de-repression. The NR1 promoter contains in the proximal region GC-boxes and MEF2 sites that interact with transcription activators sensitive to neuronal differentiation and thus could contribute to this positive mechanism (5-7). However, our recent observation suggests that the distal region of this promoter is required for fully up-regulated transcription (4) and very likely contains one or more important enhancers that positively respond to the signals of neuronal differentiation.
and plasticity. The essential component of the NMDA receptor complexes is encoded by the NR1 gene (1, 2) . This gene is induced during neurogenesis and up-regulated in neurons undergoing differentiation (3, 4) . In studies of NR1 gene upregulation, a negative mechanism has been proposed: repressor element 1 (RE1) silencing transcription factor (REST)/neuronrestriction silencer factor (NRSF) acts on the RE1 site in the NR1 promoter and suppresses transcription in neural progenitors. After neurogenesis, REST/NRSF is down-regulated, and the suppression of the NR1 gene is removed to let de-repression occur (4) . In studies of neuronal differentiation of P19 cells, we observed that there was a time gap between the down-regulation of the REST/NRSF protein and the gradually robust upregulation of the NR1 mRNA/promoter activity during neuronal differentiation (4) , suggesting that a positive mechanism is required for NR1 gene transcription after de-repression. The NR1 promoter contains in the proximal region GC-boxes and MEF2 sites that interact with transcription activators sensitive to neuronal differentiation and thus could contribute to this positive mechanism (5-7). However, our recent observation suggests that the distal region of this promoter is required for fully up-regulated transcription (4) and very likely contains one or more important enhancers that positively respond to the signals of neuronal differentiation.
Sequence analysis of the NR1 promoter uncovered a putative nuclear factor-B (NF-B) site in the region distal to the transcription start points (TSPs) (4) . NF-B sites interact with dimerized NF-B factors and positively regulates cis-promoter. Five different NF-B factors have been found in mammalian tissues, p65 (Rel-A), p50, p52, C-Rel, and RelB. Homo-or heterodimers of NF-B factors are associated with IB factor in the cytoplasm and remain inactive. Activating signals triggered by environmental cues induce IB dissociation, thus releasing NF-B dimers that then become activated and nuclearly translocated to regulate transcription of target genes (8 -10) . In the nervous system, NF-B activity is differentially distributed in the developing brain at different stages (11) . For example, p50 appears in the early gastrula stage followed by the appearance of p65/c-Rel in neurons during the postnatal period (12) . In mature neurons p65 and p50 NF-B factors are constitutively expressed, and other NF-B factors may be induced by selective stimuli, such as neuronal differentiation (11, 13, 14) . Although putative NF-B sites were found in several neuronal genes (15) (16) (17) , their impact on promoter activation during neuronal differentiation is largely undefined. NMDA receptors are also involved in brain development (2) , and activation of NMDA receptors provides the major neuronal signal for activation of the NF-B factors (13, 14) . Therefore, whether NF-B factors are able to regulate the NMDA receptor genes and thus promote their maturation may be important for retaining long term activation of NF-B factors in neurons un-dergoing differentiation or in mature neurons.
Recent studies revealed that the Sp1 transcription factor that usually binds GC-box (GGGGCGGGC) or GT (GGGTGT-GGC) motifs (18) exhibits a high affinity to a subset of NF-B sites. For example, Sp1 activates NF-B sites from the immunoglobulin -chain and P-selectin promoters (19) . NF-B factors do not, however, share binding affinity to GC-box sequences. Most recently, it was reported that in the nervous system there is a neuronal B-binding factor that binds the NF-B consensus but is distinct from all identified NF-B factors. This factor was found to be a complex consisting of Sp1, 3, and 4 (20) . These factors are activators to most genes except that Sp3 may activate genes having a single GC-box (21, 22) but repress Sp1-mediated transactivation of genes having multiple GC-boxes, possibly via competition for DNA binding sites (23, 24) . Protein modification studies also indicated that repressive Sp3 could become an activator after acetylation (25) . We have previously demonstrated that Sp factors (Sp1, 3, and 4) are activators to the NR1 promoter via an interaction with the tandem GC-boxes proximal to the TSPs (26) . Whether Sp factors also act on cis-element(s) existing in the distal region of the NR1 promoter remains unknown.
In the present study, to search for positive mechanisms underlying the up-regulation of the NR1 gene during neuronal differentiation, we functionally analyzed the putative NR1 NF-B site in P19 cells and cultured cerebrocortical neurons. We collected evidence to show that this putative site activated the NR1 promoter in cells undergoing neuronal differentiation. Additional studies demonstrated that, instead of NF-B factors, this site mainly interacted with the Sp factors to up-regulate the promoter. Furthermore, interaction of this site with Sp factors in situ was demonstrated and, finally, Sp3 binding was shown to be lost following neuronal differentiation, while Sp1 binding became enhanced.
EXPERIMENTAL PROCEDURES
Materials-Antibodies were obtained from following resources (followed by their catalogue numbers): Sp1 (07-124) from Upstate Biotechnology Inc. (Waltham, MA); Sp3 (sc13018x and sc644x), Sp4 (sc13019x and sc645x), p65 (sc-109x), p50 (sc-114x), p52 (sc-298x), and c-Rel (sc-272x) from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant proteins of p50 and p49 were purchased from Promega (Madison, WI). Oligonucleotides were synthesized by Genemed Synthesis (South San Francisco, CA).
Construction of Reporter Genes and Expression Constructs-All plasmids used in this study have been described previously (4, 27) with the following exceptions. Mutation of the NF-B site in the rat NR1 promoter was conducted with a Quick Exchange kit (Stratagene, La Jolla, CA) with primers GB402, 5Ј-TTAATGTCCTGGtaccTCCTGTCTAC, and GB403, 5Ј-GTAGACAGGAggtaCCAGGACATTAA (lowercased letters represent replaced bases) to form the construct pNRL5.4mtNFB. Plasmid pNRL5.4mtGC carrying mutation of the tandem GC-boxes was generated by exchange of the KpnI-XbaI fragment between pNRL3029mtSp1 ϫ 2 (27) and pNRL5.4 (4). Exchanging KpnI/XhoI fragments between pNRL5.4⌬RE1 (4) and pNRL5.4mtNFB produced pNRL5.4⌬RE1mtNFB bearing the RE1 deletion together with an NF-B mutation.
Preparation of Recombinant Adenovirus-Shuttle plasmid pAdTrack containing the green fluorescent protein (GFP) gene driven by the early gene promoter of human cytomegalovirus (CMV), and adenoviral backbone vector pAdEasy2 were obtained from Dr. Tong-Chuan He (Johns Hopkins University). Recombinant adenovirus rAdGFP expressing GFP was prepared using pAdTrack and AdEasy2 following the protocol described by He et al. (28) . Recombinant adenovirus rAdLacZ expressing the bacterial LacZ gene was provided generously by Dr. Christine L. Wilcox (Colorado State University). Recombinant adenovirus Ad5IB encoding an IB␣ super-repressor was a kind gift from Dr. David Brenner (University of Columbia). Amplification and titration of these viruses were accomplished by infecting HEK293 cells with virus following standard protocols (28) . Infected HEK293 cells were lysed by a freeze-and-thaw protocol. Cell debris was removed by centrifugation, and the supernatants were saved at Ϫ80°C until use.
Cell Culture, Neuronal Differentiation, Transfection, Infection, and Reporter Assay-Previously described methods were used for culture of P19 cells (4), HEK cells (5), and dissociated rat cerebrocortical neurons (27) . Differentiation of P19 cells was induced by retinoic acid (RA) as described previously (4) . Transient transfection was accomplished with LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) following the manufacturer's instruction for cells growing in 12-well plates. Expression constructs were cotransfected with promoter-luciferase genes at a 4:1 ratio in the presence of pCMV␤gal in an amount one-tenth that of the luciferase construct. Reporter gene assays and normalization of luciferase activity to ␤-galactosidase were carried out as reported previously (4) . For infection, selective rAd was added to cells by 100 plaqueforming units per cell for 24 h. Infection efficiency of differentiated P19 cells by rAd was tested with rAdGFP, and more than 80% of cells showed GFP green fluorescence 24 h after infection (data not shown).
The stable cell line of P19 cells harboring the 5.4-kb NR1 promoter (P19NR1-5.4) has been described previously (4) . Establishment of the P19 cell line carrying the mutated 5.4-kb NR1 promoter or the NF-Bluciferase gene was accomplished by cotransfection of pcDNA3 with pNRL5.4mtNFB or B-luc as described previously (4) to form P19NR1-5.4mtNFB and P19-NF-B-luc cell lines, respectively. The B-luc DNA was a gift from Dr. D. D. Billadeau (Mayor Clinic) and contains three NF-B sites upstream of the concanavalin-A minimal promoter-luciferase gene (29) .
Inactivation of NF-B by decoy DNA was performed following a protocol and utilizing DNA sequences described in the literature for cultured neurons (30) . 150 pmol of DNA was transfected by LipofectAMINE 2000 into P19 cells cultured in a 3.5-cm dish. In some experiments, decoy DNA was transfected into P19-NF-B-luc cells for 12 h, and phorbol myristate acetate (PMA, Sigma, St. Louis, MO) at 0.1 M was used to stimulate the cells for an additional 5 h before reporter gene activity was measured. DNA with a sequence scrambled from the NF-B decoy sequence served as a control to correct for the effect of transfection on the inhibition (30) . The same decoy and control DNAs were transfected into P19NR1-5.4 cells differentiated for 6 days, and 12 h later cells were harvested for luciferase assay. The luciferase assay and its normalization to cellular protein contents were accomplished for stable transfectants as described previously (4) .
DNA Protein Interaction and Immunoblot Analysis-Electrophoretic mobility shift assays (EMSAs) were performed following a protocol described previously (6) . Nuclear proteins were extracted from P19 cells as described in previous studies (4) . A probe for the rat NR1 NF-B site (rNR1-NFB) was formed by annealing DNA GB424 (upper strand, 5Ј-TTAATGTCCTGGGACTTTCCTGT) and GB425 (lower strand, 5Ј-AGTGTAGACAGGAAAGTCCCAGG) with uneven ends. A probe for the mouse NR1 NF-B site (mNR1-NFB) was produced as above with DNA GB469 (upper strand, 5Ј-TCTGAGGAGTGGGACTGGCCAGCAT) and GB460 (lower strand, 5Ј-GCCTAATGCTGGCCAGTCCCACTCC). Both rNR1-NFB and mNR1-NFB were labeled by Klenow enzyme in the presence of [␣-32 P]dCTP (Ͼ3000 mCi/mmol, ICN Biomedicals, Irvine, CA) (4). The NF-B consensus probe of the Ig/HIV promoter was obtained from Promega and 5Ј-end-labeled with [␥-32 P]ATP (Ͼ6000 Ci/mmol, ICN Biomedicals) by T4 DNA kinase (6) . This consensus has a sequence of 5Ј-AGTTGAGGGGACTTTCCCAGGC with the core sequence underlined. Competitors of the NR1 NF-B sequences were prepared by filling in the uneven ends of the annealed GB424/GB425 and GB469/GB470 with Klenow enzyme individually. Competitors containing consensus of Sp1 GC-box, the Ig/HIV NF-B, or Oct1 were purchased from Promega. Competition and supershift experiments were done as described previously (6) . Reaction buffer for NF-B binding was composed of 4% Ficoll (Sigma), 2 g of poly(dI-dC), 1 g of BSA, 60 mM KCl, 5 mM dithiothreitol, 20 mM Hepes, pH 8.3 (19) . To perform NR1 GC-box EMSA, a probe used was formed by annealing GB59 (5Ј-GCGTCAGGAAGCGGGGGCGGTGGGAGGGGTAGAACGCGTAGGT) and GB60 (5Ј-ACCTACGCGTTCTACCCCTCCCACCGCCCCCGCTTC-CTGACGC) as described previously (31) . Each experiment was repeated at least three times. Immunoblot analysis of Sp1 and Sp3 in nuclear extracts was performed using methods described previously (4, 27) .
Chromatin Immunoprecipitation-ChIP experiments were performed following the methods described by Baek (32) and Hatzis (33) as well as the instruction described by Upstate Biotechnology Inc. in a ChIP assay kit. Briefly, P19 cells were grown to more than 80% confluence and fixed with 1% formaldehyde in media for 10 min at room temperature to cross-link DNA with proteins. Reaction was terminated by addition of 0.15 M glycine. Nuclei were prepared by incubation of cells in lysis buffer (50 mM Hepes, pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.5 mM phenylmethylsul-fonyl fluoride, 1 g/ml aprotinin, 1 g/ml leupeptin) on ice for 10 min, and then centrifugation at 6,000 ϫ g for 5 min. Nuclei were dissolved in radioimmunoprecipitation assay buffer plus protease inhibitors (27) , and DNAs in lysates were sonicated into fragments between 200 and 1000 bp. Cell debris was removed by centrifugation at 16,000 ϫ g for 10 min at 4°C, and supernatants were diluted five times with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Hepes, pH 7.9, 167 mM NaCl). After clean up with protein A/G-agarose (Santa Cruz Biotechnology) saturated with 50 g/ml sheared lambda DNA and 1 mg/ml BSA in TE buffer, the diluted supernatants underwent immunoprecipitation with 5 g of Sp1 or Sp3 antibody for every 1.5-ml volume at 4°C overnight. Antibodies were recovered with protein A/G-agarose saturated with sheared lambda DNA/BSA and washed with 1 ml of the following buffers in order: once with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl); once with high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl); once with LiCl wash buffer (250 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0); twice with TE buffer, pH 8.0. DNA-protein complexes were eluted from beads twice with 100-l elution buffer (1% SDS, 100 mM NaHCO 3 ). The eluted samples were combined and each was treated with 1 g of RNase A for 15 min at 37°C. Protein-DNA cross-link was reversed by 300 mM NaCl at 65°C for 4 h. Eluants were then deproteinized by 10 g/ml proteinase K at 45°C for 2 h. Free DNAs were extracted by the conventional phenol/chloroform method. Purified DNA was dissolved in 50 l of dH 2 O. One-tenth of each DNA was amplified for 40 cycles in PCR by employing Ex Taq DNA polymerase (TaKaRa/PanVera, Madison, WI) and primers GB580 (5Ј-ATATACTGGCCCCATGGTCA) and GB581 (5Ј-TGGTGACTGGCTGTTCTCTG) to detect the fragment overlapping the mouse NR1 NF-B site. As a positive control (input), sonicated nuclear lysates underwent reverse cross-link and phenol/chloroform extraction and were subject to PCR. For negative control, an antibody against goat IgG was used in immunoprecipitation. PCR products were fractionated and visualized on 1% agarose plus 1% low melt agarose-TAE gel containing ethidium bromide (4).
RESULTS

The NR1 Gene Has a Putative NF-B Site in the Distal 5Ј
Flanking Region-Our previous observations suggest that the distal region of the rat NR1 promoter contains positive regulatory elements (4) . A motif search of this region revealed a sequence matching perfectly the 10-bp consensus of the Ig/HIV NF-B site, the most common NF-B site identified previously (10) . Its homology to the NF-B consensus, position in the NR1 promoter, and 10 bp of flanking sequences at both ends are presented in Fig. 1 . A similar putative site was also found in the distal 5Ј flanking sequences of the mouse NR1 gene from clone RP23-47P18 on chromosome 2 deposited in the GenBank TM mouse genome data base (www.ncbi.nlm.gov/genebank/mousegenom) (Fig. 1) .
The Putative NF-B Site Is an Enhancer for the NR1 Promoter during Neuronal Differentiation-Previously we have demonstrated that the distal 5Ј flanking sequence, which contains the putative NF-B site, increases NR1 promoter activity in either undifferentiated or neuronally differentiated P19 cells and that the promoter (5.4-kb) undergoes up-regulation following neuronal differentiation (4) . To elucidate the function of this putative NF-B site, we examined its impact on the upregulation of the NR1 promoter during neuronal differentiation. Initially we mutated this site in the 5.4-kb promoter by changing its sequence in length and order. The promoter containing this mutant was fused to the firefly luciferase gene, stably transfected into P19 cells, and compared in activity with the wild-type promoter during neuronal differentiation. As shown in Fig. 2 , the wild-type promoter started increasing its activity 5 days after RA treatment, a point when neuronal differentiation is ongoing, and this increase peaked by more than 75-fold promoter activity over that in undifferentiated cells. In contrast, the promoter activity of the mutant began to increase 6 days after RA treatment and reached a level less than 20-fold of promoter activity prior to differentiation. These results suggest that this NF-B site is an important enhancer to the NR1 promoter for its activation during neuronal differentiation.
Increase in p50 Nuclear Translocation and Induction of p65 Nuclear Translocation in P19 Cells Undergoing Neuronal Differentiation-Our data above demonstrated that the NF-B site is involved in activation of the NR1 promoter during neuronal differentiation. Then, we wished to know whether P19 cells have the NF-B proteins in their nuclei and whether neuronal differentiation induces the nuclear localization of these proteins, thus regulating the NR1 promoter. To address these questions, we extracted nuclear proteins from P19 cells that were induced by RA into different stages of neuronal differentiation and examined the binding capability of these extracts to an Ig/HIV NF-B consensus in EMSA. Our results, shown in Fig. 3 , indicated that nuclear proteins of undifferentiated P19 cells formed two protein-DNA complexes with the Ig/HIV NF-B consensus. The upper, slowly migrating band (B) contained the NF-B factor, p50, as shown by antibody supershift (B and C in lane 3). The fast migrating band (A) was not interfered with by any antibody tested, and its identity remains unknown. Sp1 antibody served as a control for non-related factor and did not cause any change. Interestingly, following neuronal differentiation, the binding strength of band A and B was changed dramatically (Fig. 3B) . PhosphorImager analysis revealed that radioactivity associated with band A was 5.65-fold of that with band B. Five days after RA treatment, radioactivity detected in band A was enhanced 65% over the level in undifferentiated cells, but, by 7 days of differentiation, it was less than 50% of that in undifferentiated cells. Meanwhile, radioactivity in band B was constantly increased till more than 7-fold by 7 days of RA treatment (Fig. 4A) . Such changes made the ratio of band A to band B 5.65 in undifferentiated cells and 0.41 in those treated by RA for 9 days. Further, antibody supershift experiments revealed that the enhanced band B in cells treated with RA for 8 days included not only the increased p50 factor, but also the newly translocated p65 factor (Band D, Fig. 4B ). These results indicated that undifferentiated P19 cells had p50 constitutively located in nuclei, and neuronal differentiation induced the translocation of p65 to nuclei in addition to increasing p50 nuclear translocation.
Nuclear Translocation of NF-B Factors Has a Limited Effect on the NR1
Promoter Activation-On the basis of results obtained above, we hypothesized that the NF-B factors newly translocated to nuclei might act on the putative NF-B site and thus activate the NR1 promoter. To test this hypothesis, we inhibited the nuclear translocation of NF-B factors with two approaches. First, we utilized an IB␣ super-repressor that binds NF-B factors tightly to prevent them from release and nuclear translocation (34) . Functionality of the IB␣ superrepressor was examined in P19-NF-B-luc cells (29) . After differentiation for 7 days, P19-NF-B-luc cells were infected with Ad5IB for 24 h. Afterward we measured luciferase activity and normalized it to protein contents. We observed that NF-B activity in differentiated cells was increased by 3.6-fold (mean Ϯ S.E. of relative luciferase units/g of protein: 7238.8 Ϯ 694.81 versus 1999.7 Ϯ 195.5 in undifferentiated cells, n ϭ 6), and this increase was inhibited by the IB␣ super-repressor to only 24% of that in undifferentiated cells. Then, we differentiated P19 cells bearing the 5.4-kb NR1 promoter-luciferase fusion gene for 5 and 7 days by which time an increase in NR1 promoter activity has begun (Fig. 2B) . Twenty-four hours after infecting these cells with Ad5IB, we measured luciferase activity and normalized it to cellular protein contents. To our surprise, overexpression of the IB␣ super-repressor resulted in only a limited reduction of NR1 promoter activity in cells differentiated to either 6 or 8 days in comparison to rAdLacZinfected cells. However, these reductions are significant by t test analysis (Fig. 5A) . To confirm this observation, we applied a decoy DNA to block NF-B nuclear translocation (30) . As shown in Fig. 5B , NF-B decoy DNA slightly inhibited activation of the NR1 promoter in the stable transfectants during neuronal differentiation from day 6 to 7 after RA treatment (Fig. 2) . To ensure the specificity of the decoy DNA used, we tested its capability to suppress PMA-induced activation of the NF-B-containing promoter in stable transfectant P19-NF-Bluc. We observed that PMA induced 5.6-fold increase in the reporter gene in the stable transfectants and 45.59% (S.E. ϭ 3.32 and n ϭ 6) of this increase was inhibited by the decoy DNA, whereas the control DNA with a sequence scrambled from the NF-B decoy showed no effect. Our results are consistent with previous observations for PMA (35) and NF-B decoy (30) .
The NR1 NF-B Site Interacts with Sp Proteins-Then, we wanted to ask which transcription factor virtually acted on the NR1 NF-B site and regulated the promoter in P19 cells. We applied EMSA to address this question and found that radiolabeled rNR1-NFB consisting of the rat NR1 NF-B site plus 10-bp flanking sequences at both ends (Fig. 1) formed in an NF-B binding buffer (19) a strong complex with nuclear proteins of undifferentiated P19 cells (Fig. 6) . A weak and slowly migrating complex was also observed when the reaction buffer was replaced with one for Sp1 binding (data not shown). We named this complex band I and tested its specificity with unlabeled probe as well as mNR1-NFB composed of the mouse NR1 NF-B site plus 10-bp flanking sequences at both ends. As shown by lanes 3 and 4 in Fig. 6 , band I was abolished almost completely either by unlabeled rNR1-NFB or mNR1-NFB, whereas other competitors, including the Ig/HIV NF-B, Sp1 GC-box, or Oct1 consensus, showed no effect.
To identity component(s) in band I, we utilized antibodies specific to individual NF-B factors. Surprisingly, as shown in Fig. 7A , none of these antibodies affected band I. Because the Sp1 factor may interact with the NF-B site (19) and the neuronal B-binding factor is composed of Sp proteins (20), we applied antibodies against individual Sp factors in EMSA. Interestingly, Sp3 antibody completely abolished band I (lane 3, Fig. 7B ), even though an Sp1 GC-box consensus was unable to compete out the binding (lane 5, Fig. 6 ). We also noticed that addition of Sp1 or Sp4 antibody slightly enhanced this band (Fig. 7B ). This change was more apparent when a buffer preferential for Sp binding was used (19) (data not shown). Another weak, slow migrating band was formed in the Sp buffer after overexposure gel to x-ray film and removed by the Sp1 antibody (data not shown). We further tested the binding capability of the mouse NF-B site and obtained similar results except that mNR1-NF-B formed three complexes (bands 1-3) with P19 nuclear proteins. The middle band (band 2) was interfered with by the Sp3 antibody, whereas bands 1 and 3 were removed by the Sp1 antibody (Fig. 7C) . To trace whether neuronal differentiation has any impact on this binding, we performed EMSA with the same group of nuclear proteins tested in Fig. 4 for the Ig/HIV NF-B site. At the early stage of differentiation, we observed moderate increases in binding of 36.99% and 43.31% in cells differentiated for 5 and 6 days, respectively. Interestingly, following further differentiation, the binding declined (Fig. 8A ) even though these nuclear extracts contained an increased amount of p50 and newly translocated p65 (Fig. 4) . This modulation may be caused by Sp protein level or by modulation of the binding properties of Sp3. To address these issues, first we measured Sp3 and Sp1 protein levels in these nuclear proteins. As shown Fig. 8B , Sp1 antibody revealed a single band of about 105 kDa as reported previously (36) , and this band was intensified following neuronal differentiation. Analysis of the band intensity indicates a 4.5-fold increase 9 days after RA treatment. Sp3 antibody detected two major bands representing a full-length protein of 100 kDa and a splice variant of 60 kDa (Fig. 8C) as reported previously (37) . In contrast to Sp1, the Sp3 protein level increased in the early stage of neuronal differentiation and then quickly decreased to undetectable levels 9 days after RA treatment. Our previous studies indicated that Sp proteins, mainly Sp1, interacted with the tandem GC-boxes in the NR1 promoter (6) . Then, to view the behavior of this interaction during neuronal differentiation, we performed EMSA with a probe covering these tandem GCboxes. Results shown in Fig. 8D demonstrated that the binding was attenuated at the beginning of neuronal differentiation and afterward robustly increased 4.5-fold as calculated by quantitative analysis of the gel on PhosphorImager. These results suggest that Sp3 may act on the NR1 NF-B site in the early stage of neuronal differentiation, whereas Sp1 may be a major player in the later stage of neuronal differentiation by interacting with both the NF-B site and GC-boxes.
In view of the results shown in Figs. 4 -7, one may question whether the NR1 promoter has a real NF-B site or just another Sp binding site. To address this concern, we tested the binding capability of the NR1-NF-B site with purified recombinant human NF-B factors: p50 or p49, a splice variant of p52 from a common precursor, p100 (38) . We found that either rat or mouse NR1-NFB DNA was strongly bound not only by p50 or p49 alone but also by their combination indicating a viable heterodimer of p50/p49 (data not shown). Our results suggest that the NR1 promoter indeed has a bona fide NF-B site.
Sp Factors Up-regulate the NR1 Promoter by Acting on Both the NF-B Site and GC-boxes-Results obtained above suggest
that Sp factors may regulate the NR1 promoter by interacting with a new binding site in addition to the previously identified GC-boxes (6) . To further evaluate the functional outcome of this new interaction, we cotransfected the 5.4-kb NR1 promoter-reporter fusion gene with various Sp expression constructs into undifferentiated P19 cells. As shown in Fig. 9A , NR1 promoter activity was enhanced by overexpressed Sp factors even in the presence of the RE1 site in the promoter. It has been known that this RE1 site interacts with a transcription suppressor, REST/NRSF, which is abundant in undifferentiated P19 cells (4) . Sp1 increased promoter activity 3-fold, whereas others factors increased activity ϳ1.5-fold. The NR1 promoter with mutation of the NF-B site or GC-boxes lost responsiveness to Sp factors and showed activity comparable to that seen in cells cotransfected with vector (Fig. 9A) . We assumed that the high level of REST/NRSF in P19 cells (4) might negatively block the effects of Sp factors on the promoter. To test this assumption, we mutated the RE1 site from the promoter and examined the effect of individual Sp factors on the promoter again. As indicated in Fig. 9B , RE1 mutation allowed the promoter to be regulated by Sp1 factor more strongly, up to more than 5-fold. Interestingly, cotransfection of Sp4 also produced a more than 4-fold increase, whereas Sp3 produced an increase of only slightly above a 2-fold. Taken together, results above suggest that undifferentiated cells lack sufficient Sp factors to overcome the repression caused by REST/NRSF or the latter is sufficient to inhibit the promoter regardless the presence of Sp factors in the cells.
Results shown in Fig. 2 indicated that during neuronal differentiation the NF-B site enhanced NR1 promoter activation. In addition, results in Fig. 8 revealed that EMSA experiments were performed as described in Fig. 2 with radiolabeled rNR1-NFkB. Nuclear proteins were preincubated with antibodies against individual NF-B factors as indicated before the probe was added. B, the NF-B site of the rat NR1 promoter interacted with an Sp3-like protein in P19 cells. EMSA experiments were performed as described above. Nuclear proteins were preincubated with antibody specific for Sp1, Sp3, or Sp4 as indicated. C, the mouse NR1 NF-B site interacted with Sp proteins in P19 cells. EMSA experiments were performed for radiolabeled mNR1-NFB with nuclear proteins extracted from undifferentiated P19 cells. Nuclear proteins were preincubated with indicated antibody before probe addition. Bands 1 and 2 were interrupted by Sp3 antibody, whereas band 3 was removed by Sp1 antibody. tial effects of individual Sp factors in neurons. To explore these possible effects, first we cotransfected Sp factors with NR1 promoter-reporter constructs containing a wild type or a mutated NF-B site or GC-boxes into neuronally differentiated P19 cells. Before transfection, differentiated P19 cells had been treated with 1-␤-D-arabinofuranosylcytosine to eliminate glial cells and enrich neurons. As shown in Fig. 10A , coexpression of Sp factors increased NR1 promoter activity. Although the -fold increase in promoter activity relative to vector alone was similar to what had been seen in undifferentiated cells, promoter activity before overexpression of Sp factors was 7-fold of that obtained in undifferentiated P19 cells. Importantly, mutation of the NF-B site abolished totally the effect of coexpressed Sp3 and, significantly, that of Sp1 and Sp4. Mutation of the GCboxes also completely removed all enhancement derived from coexpressed Sp factors. Next, we examined effects of Sp factors on the promoter in cultured cerebrocortical neurons in which more than 95% cells were positive to microtubular-associated protein-2 immunostaining (4). Interestingly, we obtained the same results as what we observed in differentiated P19 cells except that Sp3 and Sp4 produced more than a 4-fold increase in promoter activity, whereas Sp1 exhibited only ϳ2-fold increase (Fig. 10B) . Once again, these enhanced activities became significantly attenuated when the NF-B site or GC-box was mutated (Fig. 10B) .
The NR1 NF-B Site Interacted with Sp Factors in Situ-
Because EMSA is accomplished between isolated nuclear proteins and DNA fragments or oligonucleotides, it is not a direct measure of in vivo protein-DNA interaction in the presence of complex chromatin structures. To ensure that Sp factors do have the capability to directly bind the NR1 NF-B site in living cells, we employed a ChIP assay to cross-link the DNA with bound proteins in situ in P19 cells and precipitated the protein-DNA complexes with antibody specific for Sp1 or Sp3. Then, we measured DNA fragments containing the NR1 NF-B site by PCR. As shown in Fig. 11 , PCR with primers flanking the NR1 NF-B site produced a band from DNA coprecipitated with Sp1 or Sp3 (Fig. 11 ). This band migrated on an agarose gel to a position identical to the genomic DNA control (input). In a negative control, immunoprecipitation with an antibody against goat IgG did not generate any PCR product. The fidelity of the PCR products was further confirmed by digestion of the DNA with MscI (data not shown). Consistent with the results of cotransfection studies above, Sp3 interaction with this site in situ became undetectable after 7 days of RA treatment, while Sp1 interaction became stronger (Fig. 11) . Therefore, we believe that Sp1 and Sp3 proteins interact with the NF-B site in living P19 cells, and this site becomes nonpermissive to Sp3 after neuronal differentiation but more accessible to Sp1. 
FIG. 10. Effects of Sp factors and their binding sites on the NR1 promoter in neurons.
A, Sp factors positively regulate the NR1 promoter in neuronally differentiated P19 cells by acting on both distal NF-B site and the proximal GC-boxes. Sp expression constructs were cotransfected with wild-type (wt) or mutated NR1 promoter (5.4 kb) into P19 cells differentiated by RA for 5 days and reporter gene activities were measured 1 day after transfection. Luciferase activity normalized to ␤-galactosidase activity was used to calculate -fold increase over those cotransfected with vector (pCDNA3). B, Sp factors positively regulate the NR1 promoter by acting on both distal NF-B site and the proximal GC-boxes. Sp expression constructs were cotransfected with wild-type (wt) and mutated NR1 promoter (5.4 kb) as indicated into cerebrocortical neurons cultured in vitro for 7 days. The -fold increase in promoter activity was calculated as in A. Mean values Ϯ S.E. from six experiments are presented. DISCUSSION NF-B factors are stored in an inactive state in the cytoplasm until activating signals induce their translocation to the nucleus where they regulate gene expression. NF-B factors in the nervous system have been implicated in neuronal survival, death, plasticity, and brain development (8, 9, 13, 39) . In this study, in an effort to search for enhancers important for NR1 promoter activation during neuronal differentiation, we identified and functionally analyzed a putative NF-B site. Initially, we observed that mutation of the NF-B site significantly reduced activation of the NR1 promoter during neuronal differentiation. In addition, consistent with previous studies of NF-B activity in the developing brain (11, 13, 14) , we found that NF-B factors became activated and translocated to the nucleus following neuronal differentiation. These observations suggested a possible connection between NF-B nuclear translocation and activation of the NR1 promoter. To test this possibility, we blocked nuclear translocation of NF-B factors with the IB␣ super-repressor (34, 40) and NF-B decoy (30) . Surprisingly, activation of the NR1 promoter is not highly sensitive to this blockade (Fig. 5) . Then, we found that this putative NF-B site interacted mainly with Sp factors, although it matches perfectly the most popular consensus and was capable of interacting with recombinant NF-B factors p50 or p49 in vitro. To explore the functional consequence of this interaction, we cotransfected the wild-type or mutated promoter-reporter gene with various Sp expression constructs into cultured cells. Our data further revealed that Sp factors had a positive effect on the NR1 NF-B site and that the contribution of distinct Sp factors to this effect was regulated by neuronal differentiation with an enhancement of Sp1 and a reduction of Sp3.
It is well known that transcription factors specifically bind selective DNA sequences that have a limited variation following a consensus. In certain cases, one type of consensus can be bound by different groups of transcription factors (41) , and one group of transcription factors may interact with a different consensus (42) . For example, Sp factors may bind GC-boxes, GT motifs, or basic transcription elements (18) . NF-B factors and Sp factors belong to different families of transcription factors based on distinct DNA consensuses and protein structures. It was reported previously that NF-B and Sp cooperatively activated the human immunodeficiency virus type 1 gene when their cognate binding sites are close together on the promoter (43) . In our studies, however, Sp factors selectively bind to the NR1 NF-B site. This selection is clearly not due to a lack of the NF-B factors in the nucleus, because the Ig/HIV NF-B consensus was bound by the NF-B factors, p50 and p65, from the same nuclear preparation (Fig. 3) . Therefore, affinity may be the mechanism underlying the diversity seen between these two NF-B sites. Hirano et al. (19) reported previously that Sp factors in nuclear proteins extracted from HeLa cells interacted with a subgroup of NF-B sites, but in their studies bindings of NF-B and Sp factors coexisted to the same probe, suggesting similar affinities of these factors to the DNA. Interestingly, in the present studies, sequence comparison indicates that these two sequences used in EMSA (Fig. 1) share exactly the same 10-bp consensus, but have distinct flanking sequences. Therefore, the flanking sequence may determine selectivity of transcription factors. It was reported previously that nucleotide residues directly flanking the 10-bp NF-B consensus had an impact on its affinity to NF-B factors (44) . For example, replacement of the first G residue 5Ј of the 10-bp NF-B consensus reduces its affinity to p50 homodimer, but not p50-p65 heterodimer (44) . Recently, we also observed that the flanking sequence is required for REST/NRSF binding to the RE1 site in the NR1 promoter (4) . However, in this study, we observed a new phenomenon that flanking sequence may determine which protein the NF-B consensus binds, NF-B factors or Sp factors. This selection may result from the large difference of the affinities of these transcription factors to the DNA. The NR1 NF-B site was able to bind recombinant NF-B proteins but interacted almost exclusively with Sp factors when the DNA probe was incubated with crude nuclear extracts in which both families of Sp and NF-B factors exist. This possibility is further supported by an observation that neither a GC-box consensus nor the Ig/HIV NF-B site competed interaction between Sp factors and the NR1 NF-B site (Fig. 6 ). We cannot, however, exclude the possibility that this selection may depend on the components in nuclear extracts or status of protein modification. For example, many transcription factors interact with each other and then regulate the cis-promoter. A great body of data has revealed that Sp factors interact with other transcription factors, including NF-B factors (45) . Again, posttranslation modification may modulate these interactions and thereby increase the complexity of gene expression as well as link gene transcription to signal transduction. This possibility is supported by the fact that both NF-B factors and Sp factors can be modified via phosphorylation (46) or acetylation (47) , thus changing their relationship with DNA. Our previous studies have indicated that signaling of nerve growth factor, which is involved in neuronal differentiation, causes phosphorylation of Sp1 and thus modifies its action on the NR1 promoter (26) . The impact of protein modification of other Sp factors on their regulation of the NR1 promoter during neuronal differentiation is currently under investigation in our laboratory.
In this study, although we did not detect apparent binding activity of NF-B factors to the NR1 NF-B site from P19 cells, inhibition of nuclear translocation of NF-B factors indeed reduced, even by a small scale, the NR1 promoter activity. Furthermore, the NR1 NF-B site is able to bind purified recombinant NF-B factors. Therefore, it is still possible that NF-B factors may increase their binding affinity to this site and thus regulate the NR1 gene transcription in a competition with Sp factors. Several lines of studies suggest that this possibility may be true. For example, Qin et al. reported that an endogenous NMDA agonist, quinolinic acid, induced nuclear translocation of NF-B factors in the rat striatal neurons (48) and a down-regulation of NMDA receptor binding followed (49) . This may be relevant to NR1 regulation, because we observed a down-regulation of NR1 mRNA following the time of the nuclear translocation of NF-B factors in quinolinic acid-injected striatum. 2 Because activation of glutamate receptors induces the nuclear translocation of NF-B factors (13, 14) , it is also possible that NF-B factors are involved in a negative autoregulation of the NR1 transcription. For example, Mao et al. (20) reported that glutamate stimulation down-regulated 2 Y. Chai and G. Bai, unpublished data. NR1 mRNA in cultured neocortical neurons. The detailed mechanism regarding the role of NF-B factors in the NR1 transcription needs further investigation.
In this study, we observed that Sp factors were able to up-regulate the NR1 promoter even in undifferentiated P19 cells. Taken together with our previous report that deletion of the negative cis-element RE1 releases NR1 promoter activity robustly (4), one might assume that undifferentiated cells have enough activators for the NR1 gene transcription and the derepression is the only key factor in NR1 promoter activation. However, in P19 cells, REST/NRSE is down-regulated 4 days after RA treatment (4) . At the same time, NR1 promoter activity remains at a very low level and only begins to increase 6 days after RA treatment. Furthermore, this increase lasts more than 2 days (Fig. 2) . Therefore, a change of transactivators is still required for the NR1 promoter. Sp factors very likely contribute to this effect. This likelihood is supported by the following facts: 1) cotransfection of Sp factors with an NR1 promoter lacking the RE1 site into undifferentiated P19 cells gained much more activation of the promoter (Fig. 9B) , suggesting a shortage of Sp factors in the cells; 2) differentiated P19 neurons or cerebrocortical neurons activated the NR1 promoter a much high level than undifferentiated P19 cells and overexpression of Sp factors resulted in less up-regulation of the NR1 promoter, indicating that neurons already have a high level activators like Sp factors; and 3) Sp1 binding to the NR1 GC-box undergoes dynamic changes during neuronal differentiation; it is down-regulated at the early stage and up-regulated robustly in the late stage (Fig. 8D) . Meanwhile, the nuclear Sp1 level is moderately increased, whereas the nuclear Sp3 level increased in the early stage and robustly decreases in the late stage of neuronal differentiation (Fig. 8B) .
Sp factors share similar C-terminal zinc-finger DNA binding domain, and Sp1, 3, and 4 bind DNA with a similar affinity, even though they may differentially regulate the transcription (42) . For example, Sp3 represses several promoters that positively respond to Sp1 (23), whereas Sp3 and Sp1 both activate some promoters (21, 22, 27) , including the GC-boxes of the NR1 promoter (26) . From data of the current study, we believe that Sp1, 3, and 4 are activators of the NR1 promoter via interaction with the NF-B site. Interestingly, we observed differential effects of Sp factors on the NR1 promoter. Sp3 activated the NR1 NF-B site with the least strength but retained the highest binding affinity in vitro with P19 nuclear proteins. In comparison, Sp1 demonstrated the strongest activation of the NR1 promoter, while having a much lower binding affinity than Sp3. However, our ChIP data demonstrated that the interaction of this site in situ in well differentiated P19 cells favors Sp1 over Sp3 (Fig. 11) . Therefore, we hypothesize that that Sp3 occupies the enhancer sequence and inefficiently regulates the promoter in undifferentiated cells or cells at the early stage of neuronal differentiation. Following neuronal differentiation, Sp1 may gain high binding affinity and replace Sp3 to up-regulate NR1 transcription, because Sp1 cotransfection showed the strongest effect in differentiated P19 cells. This hypothesis is further supported by evidence from the present study. First, application of Sp1 or Sp4 antibody in EMSA increased Sp3 binding, indicating a competition among these factors. Second, neuronal differentiation robustly increased Sp1 binding to the NR1 GC box as well as nuclear Sp1 protein level (Fig. 8) . Last, the NR1 NF-B site becomes nonpermissive to Sp3 after neuronal differentiation (Fig. 11 ). Our hypothesis is also supported by the previous reports. For example, studies of mouse L cells demonstrated that Sp3 protein competes with Sp1 for the binding site but does not synergize the promoter via interaction with other cis-elements like Sp1 does (24) . Synergistic effects of different DNA cis-elements via transcription factors may be important for robust up-regulation of the NR1 gene during neuronal differentiation. Our previous studies also revealed that Sp1 is interacting with Mef2C to up-regulate the NR1 promoter synergistically in neurons (5) . Because Sp3 is unable to produce such synergistic effect, differentiating neurons may generate a mechanism to let the promoter be nonpermissive to this factor, but still permissive to Sp1. This mechanism may underlie the missing of Sp3 interaction with the NR1 NF-B site in differentiated P19 cells. Earlier studies also indicated that Sp3 repressed Sp1-mediated promoter activation (23) . In addition, Sp factors may undergo covalent modifications and thus change their functionality. For example, the Sp1 protein may be modified by multiple kinases and gain different DNA binding affinities (18, 26, 50) . Sp3 may be acetylated and switch from a repressor to an activator (25) . Whether and how these changes occur after neuronal differentiation is a very interesting question and needs further investigation.
The function of Sp factors in cultured embryonic neurons could be slightly different, because Sp3 displayed the strongest effect on the promoter (Fig. 10B) . This difference may be caused by the high heterogeneity of the cell population. Mao et al. also reported that nuclear proteins extracted from cultured neurons formed with the NF-B consensus a single complex that could be disrupted only by mixed antibodies against Sp1, Sp3, and Sp4, but not by any antibody against NF-B factors. In contrast, we saw Sp3 and Sp1 separately interacted with the NR1 NF-B site. Sp4 is distributed mainly in the central nervous system (51), and we found that it exerts a strong effect on the NR1 promoter in neurons. In summary, we believe that all Sp factors are transactivators of the NR1 promoter and act on the NF-B site as well as the GC-boxes. Neuronal differentiation may differentially modify the interaction between individual Sp factors and these two cis-elements using undefined mechanism(s) and, thus, up-regulate the transcription of the NR1 gene.
